AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

by Barry101 | Apr 29, 2024 | Press Release

Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the combination of...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Apr 25, 2024 | Press Release

OCALA, Fla., April 25, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Apr 18, 2024 | Press Release

OCALA, Fla., April 18, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

by Barry101 | Apr 15, 2024 | Press Release

OCALA, Fla., April 15, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Apr 11, 2024 | Press Release

OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...